BAMF
CORT icon

BI Asset Management Fondsmaeglerselskab’s Corcept Therapeutics CORT Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59K Buy
+683
New +$41.2K ﹤0.01% 642
2025
Q2 		– Sell
-83,227
Closed -$9.51M – 776
2025
Q1 		$9.51M Buy
+83,227
New +$5.07M 0.11% 166
2024
Q1 		– Sell
-12,851
Closed -$417K – 738
2023
Q4 		$417K Buy
12,851
+1,935
+18% +$53.1K 0.01% 571
2023
Q3 		$297K Buy
+10,916
New +$316K 0.01% 569
2023
Q2 		– Sell
-101,017
Closed -$2.19M – 756
2023
Q1 		$2.19M Buy
+101,017
New +$2.21M 0.06% 222
2021
Q3 		– Sell
-154,761
Closed -$3.4M – 373
2021
Q2 		$3.4M Buy
154,761
+46,423
+43% +$1.03M 0.13% 141
2021
Q1 		$2.58M Buy
+108,338
New +$2.89M 0.1% 158

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's CORT Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 683 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #642 among its holdings. This is a return to the name: BI Asset Management Fondsmaeglerselskab previously reported a position in CORT as recently as Q1 2025.

BI Asset Management Fondsmaeglerselskab first reported a position in CORT in Q1 2021 and has held it in 7 quarters since. The position peaked at $9.51M in Q1 2025. 205 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • BI Asset Management Fondsmaeglerselskab held 683 shares of Corcept Therapeutics worth $59K as of Q2 2026.
  • Corcept Therapeutics was a new BI Asset Management Fondsmaeglerselskab position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #642 holding.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Corcept Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • BI Asset Management Fondsmaeglerselskab's Corcept Therapeutics position peaked at $9.51M in Q1 2025.
  • 205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.